CN101448497B - 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用 - Google Patents

包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用 Download PDF

Info

Publication number
CN101448497B
CN101448497B CN2007800077942A CN200780007794A CN101448497B CN 101448497 B CN101448497 B CN 101448497B CN 2007800077942 A CN2007800077942 A CN 2007800077942A CN 200780007794 A CN200780007794 A CN 200780007794A CN 101448497 B CN101448497 B CN 101448497B
Authority
CN
China
Prior art keywords
interferon
patient
treatment
nitazoxanide
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800077942A
Other languages
English (en)
Chinese (zh)
Other versions
CN101448497A (zh
Inventor
J·-F·罗西诺尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Romark Laboratories LC
Original Assignee
Romark Laboratories LC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Romark Laboratories LC filed Critical Romark Laboratories LC
Publication of CN101448497A publication Critical patent/CN101448497A/zh
Application granted granted Critical
Publication of CN101448497B publication Critical patent/CN101448497B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
CN2007800077942A 2006-01-09 2007-01-09 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用 Expired - Fee Related CN101448497B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US75703606P 2006-01-09 2006-01-09
US60/757,036 2006-01-09
PCT/US2007/000574 WO2007081974A2 (en) 2006-01-09 2007-01-09 Viral hepatitis treatment

Publications (2)

Publication Number Publication Date
CN101448497A CN101448497A (zh) 2009-06-03
CN101448497B true CN101448497B (zh) 2013-07-10

Family

ID=38257004

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800077942A Expired - Fee Related CN101448497B (zh) 2006-01-09 2007-01-09 包含硝唑尼特、替唑尼特、或其混合物的组合物在制备治疗丙型肝炎药物中的应用

Country Status (17)

Country Link
US (3) US8633230B2 (cg-RX-API-DMAC7.html)
EP (1) EP1976516B9 (cg-RX-API-DMAC7.html)
JP (2) JP5185826B2 (cg-RX-API-DMAC7.html)
CN (1) CN101448497B (cg-RX-API-DMAC7.html)
AP (1) AP2907A (cg-RX-API-DMAC7.html)
AU (1) AU2007204963B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0706379A2 (cg-RX-API-DMAC7.html)
CA (1) CA2636527C (cg-RX-API-DMAC7.html)
DK (1) DK1976516T3 (cg-RX-API-DMAC7.html)
EA (1) EA015560B1 (cg-RX-API-DMAC7.html)
ES (1) ES2422556T3 (cg-RX-API-DMAC7.html)
IL (1) IL192548A (cg-RX-API-DMAC7.html)
MX (1) MX2008008723A (cg-RX-API-DMAC7.html)
NZ (1) NZ569507A (cg-RX-API-DMAC7.html)
UA (1) UA100840C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007081974A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA200806310B (cg-RX-API-DMAC7.html)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006235490A1 (en) * 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
CA2694440A1 (en) * 2007-07-25 2009-01-29 Biolex Therapeutics, Inc. Controlled release interferon drug products and treatment of hcv infection using same
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.
AU2010226857B2 (en) 2009-03-20 2016-07-14 University Of Virginia Patent Foundation Broad spectrum benzothiophene-nitrothiazolide and other antimicrobials
CN105853415A (zh) 2009-05-12 2016-08-17 罗马克实验室有限公司 卤代烷基杂芳基苯甲酰胺化合物
BRPI1014322A2 (pt) 2009-06-26 2015-08-25 Romark Lab Lc Método para tratar infecção, e para interromper ou evitar a produção de partículas virais infecciosas, combinação, e, composição farmacêutica.
US9333193B2 (en) 2010-09-20 2016-05-10 University Of Virginia Patent Foundation Compositions and methods for treating tuberculosis
CN107096032A (zh) 2011-05-16 2017-08-29 罗马克实验室有限公司 在有需要的对象中刺激免疫应答的方法
CN102805747B (zh) * 2011-06-01 2013-09-18 漳州片仔癀药业股份有限公司 2-(4-吗啉苯胺)-6-环己基氨基嘌呤及其药学上可接受的盐在制药中的用途
DE112012003510T5 (de) 2011-10-21 2015-03-19 Abbvie Inc. Verfahren zur Behandlung von HCV umfassend mindestens zwei direkt wirkende antivirale Wirkstoffe, Ribavirin aber nicht Interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
CN104023726A (zh) 2011-10-21 2014-09-03 艾伯维公司 用于治疗hcv的一种或多种daa的联合治疗(例如,与abt-072或abt-333)
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
US9498441B2 (en) 2012-01-27 2016-11-22 Siegfried Rhein S.A. De C.V. Nitazoxadine composition and process to prepare same
JP6633092B2 (ja) 2014-11-11 2020-01-22 ロマーク ラボラトリーズ,リミティド カンパニー チゾキサニド、その類似体又は塩のプロドラッグを用いる組成物及び治療方法
WO2016123073A1 (en) 2015-01-26 2016-08-04 Children's Medical Center Corporation Treatment of infectious diseases
HK1250945A1 (zh) 2016-03-31 2019-01-18 罗马克实验室有限公司 用於治疗病毒性感染的噻唑化物化合物
SI3442580T1 (sl) * 2016-04-11 2021-01-29 Genfit Metode zdravljenja holestatičnih in fibrotičnih bolezni
US20170290814A1 (en) * 2016-04-11 2017-10-12 Genfit Methods of treatment of cholestasis and fibrosis
JP7129703B2 (ja) 2016-04-28 2022-09-02 エモリー ユニバーシティー アルキン含有ヌクレオチド及びヌクレオシド治療組成物並びにそれらに関連した使用
WO2018140504A1 (en) 2017-01-24 2018-08-02 Patel Manoj K Compositions and methods for blocking sodium channels
EP3573614B1 (en) * 2017-01-27 2024-11-20 Genfit Pharmaceutical compositions for combination therapy
SG11201907673YA (en) * 2017-03-13 2019-09-27 Genfit Pharmaceutical compositions for combination therapy
US11173149B2 (en) 2017-04-18 2021-11-16 Romark Laboratories L.C. Inhibition of protein disulfide-isomerase A3
US11547699B2 (en) 2017-11-17 2023-01-10 Hubert Köster [2-[(5-nitro-1,3-thiazol-2-yl)carbamoyl]phenyl]ethanoate for use in lymphangioleiomyomatosis and other diseases
CN109364067B (zh) * 2018-11-17 2020-07-28 王海玲 一种化合物在制备提高血脑屏障通透性药物中的用途
US12208087B2 (en) 2019-04-09 2025-01-28 Genfit Combination of nitazoxanide and elafibranor for the treatment of immune diseases or inflammation
WO2021016543A1 (en) * 2019-07-25 2021-01-28 Romark Laboratories L.C. Antiviral combinations of thiazolide compounds
CN111012788B (zh) * 2019-12-12 2021-01-15 武汉职业技术学院 硝唑尼特和替唑尼特在制备抗猪繁殖与呼吸综合征病毒药物中的应用
JP2023537237A (ja) 2020-07-20 2023-08-31 ロマーク ラボラトリーズ,リミティド カンパニー チゾキサニドおよび2-ヒドロキシ-n-(5-クロロ-1,3-チアゾル-2-イル)ベンズアミド(rm-4848)とエタノールアミン、モルホリン、プロパノールアミン、ピペラジン、およびn-メチルピペラジンの結晶塩
IL300801A (en) 2020-08-24 2023-04-01 Romark Laboratories Lc Use of thiazolides against the corona virus
KR20240006588A (ko) * 2021-05-11 2024-01-15 장피트 패혈증의 치료에서의 니타족사나이드
CN114259492A (zh) * 2021-12-21 2022-04-01 中以海德人工智能药物研发股份有限公司 硝唑尼特在治疗乙肝中的应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1437800A (en) 1973-08-08 1976-06-03 Phavic Sprl Derivatives of 2-benzamido-5-nitro-thiazoles
GB1440212A (en) 1973-08-29 1976-06-23 Phavic Sprl Derivatives of 2-phenoxyacetamido-5-nitrothiazoles
US4315018A (en) 1978-12-07 1982-02-09 Rossignol Jean F Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
SI0755386T1 (en) * 1994-04-13 2002-10-31 Romark Laboratories, L.C. Benzamide derivative, compositions containing said derivative and use thereof
US5578621A (en) 1994-09-08 1996-11-26 Romark Lab Lc Benzamide derivatives
US5387598A (en) 1994-04-13 1995-02-07 Rossignol; Jean-Francois Composition and galenic formulation suitable for combatting affections of the lower abdomen
US5968961A (en) 1997-05-07 1999-10-19 Romark Laboratories, L.C. Pharmaceutical compositions of tizoxanide and nitazoxanide
US5859038A (en) 1994-09-08 1999-01-12 Romark Laboratories, L.C. Method for treatment of helicobacter pylori infections
US5965590A (en) 1994-09-08 1999-10-12 Romark Lab Lc Method for treatment of opportunistic infections with pharmaceutical compositions of tizoxanide and nitazoxanide
MX9604483A (es) 1994-09-08 1998-02-28 Jean-Francois Rossignol Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
US5856348A (en) 1994-09-08 1999-01-05 Romark Laboratories, L.C. Method for treatment of trematodes with pharmaceutical compositions of tizoxanide and nitazoxanide
US6576636B2 (en) 1996-05-22 2003-06-10 Protarga, Inc. Method of treating a liver disorder with fatty acid-antiviral agent conjugates
SI20149B (en) 1997-05-07 2001-08-31 Romark Lab Lc Pharmaceutical compositions of tizoxanide and nitazoxanide
US5935591A (en) 1998-01-15 1999-08-10 Romark Laboratories, L.C. Method for treatment of equine protozoal myeloencephalitis with thiazolides
DE69901321T2 (de) * 1998-05-15 2002-12-12 Schering Corp., Kenilworth Kombinationstherapie enthaltend Ribavirin und Interferon alpha bei Patienten mit chronischer Hepatitis C Infektion, die nicht antiviral vorbehandelt sind
US5925622A (en) 1998-07-13 1999-07-20 Romark Laboratories, L.C. Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
US6180136B1 (en) 1998-11-10 2001-01-30 Idexx Laboratories, Inc. Phospholipid-coated microcrystals for the sustained release of pharmacologically active compounds and methods of their manufacture and use
US6340696B1 (en) 1999-03-31 2002-01-22 The Procter & Gamble Company Viral treatment
US7125568B2 (en) 2001-08-23 2006-10-24 Sung Michael T Lipophilic drug compositions
EP1562617B1 (en) 2002-10-29 2006-12-20 Council of Scientific and Industrial Research New use of pipataline
US7081260B2 (en) 2002-10-29 2006-07-25 Council Of Scientific And Industrial Research α-Glucosidase inhibitors from a natural source
CA2520853A1 (en) * 2003-03-28 2005-03-31 Centocor, Inc. Anti-amyloid antibodies, compositions, methods and uses
US7410979B2 (en) 2003-11-19 2008-08-12 Rigel Pharmaceuticals, Inc. Synergistically effective combinations of dihaloacetamide compounds and interferon or ribavirin against HCV infections
UA90864C2 (en) 2004-09-09 2010-06-10 Ромарк Лебораториз, Л.К. Halogenated benzamide derivatives
US20060194853A1 (en) 2004-10-08 2006-08-31 Rossignol Jean F Alkyl benzamides
AU2006235490A1 (en) 2005-04-12 2006-10-19 Romark Laboratories, L.C. Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
MX2008008723A (es) * 2006-01-09 2008-09-26 Romark Lab Lc Tratamiento de la hepatitis viral.
MX381895B (es) * 2009-02-13 2025-03-13 Romark Laboratories Lc Formulaciones farmaceuticas de liberacion controlada de nitazoxanida.

Also Published As

Publication number Publication date
CA2636527C (en) 2016-05-17
US8633230B2 (en) 2014-01-21
AU2007204963A1 (en) 2007-07-19
CN101448497A (zh) 2009-06-03
US20140112888A1 (en) 2014-04-24
AP2907A (en) 2014-05-31
UA100840C2 (ru) 2013-02-11
ES2422556T3 (es) 2013-09-12
EP1976516B9 (en) 2013-10-30
CA2636527A1 (en) 2007-07-19
BRPI0706379A2 (pt) 2011-03-22
AP2008004550A0 (en) 2008-08-31
JP2010070566A (ja) 2010-04-02
IL192548A0 (en) 2009-02-11
WO2007081974A2 (en) 2007-07-19
EA015560B1 (ru) 2011-08-30
EA200870164A1 (ru) 2008-12-30
EP1976516B1 (en) 2013-04-24
JP2009522371A (ja) 2009-06-11
HK1123733A1 (en) 2009-06-26
WO2007081974A3 (en) 2008-01-17
USRE47404E1 (en) 2019-05-28
ZA200806310B (en) 2009-12-30
US20070167504A1 (en) 2007-07-19
AU2007204963B2 (en) 2012-09-27
IL192548A (en) 2015-08-31
US9107913B2 (en) 2015-08-18
DK1976516T3 (da) 2013-07-15
JP5185826B2 (ja) 2013-04-17
EP1976516A2 (en) 2008-10-08
NZ569507A (en) 2011-11-25
MX2008008723A (es) 2008-09-26
EP1976516A4 (en) 2009-11-11

Similar Documents

Publication Publication Date Title
CN101448497A (zh) 病毒性肝炎治疗
JP2009522371A5 (cg-RX-API-DMAC7.html)
US11957931B2 (en) Compositions and methods for treating vitiligo
CN102026641A (zh) 并用或组合dpp-iv抑制剂和其它糖尿病治疗药的药品
CN103096891A (zh) 利用羟氯喹或羟氯喹和抗病毒剂的组合治疗丙型肝炎病毒相关疾病
CN102105153A (zh) 使用sglt2抑制剂和含其组合物治疗高尿酸血症的方法
JP7111811B2 (ja) がんの治療に使用するためのミルシクリブの製剤及びその治療的組み合わせ
JP2013508425A (ja) Bi201335、インターフェロンアルファおよびリバビリンを含むhcvの併用療法のための投薬処置計画
JP2008515816A (ja) カスタノスペルミンを含有する、併用抗ウイルス組成物およびその使用方法
JPH11269076A (ja) 抗線維化剤
CN101204578A (zh) 一种具有调节免疫、抗组织损伤及再生修复作用的胸腺素复合制剂
CN118178405A (zh) 甲苯咪唑在制备预防或治疗肝纤维化药物中的应用
CN115671105A (zh) Ly2922470在制备预防或治疗肾脏疾病药物中的应用
CN115429871B (zh) 司美格鲁肽新用途
HK1123733B (en) Viral hepatitis treatment
US7846901B2 (en) Method for inhibiting or treating intestinal damage caused by radiotherapy or chemotherapy comprising administering substance-P
TW202606762A (zh) 治療t細胞淋巴瘤之組合物及方法
Hwang et al. Dose-dependent glucosuria of DWP16001, a novel selective SGLT-2 inhibitor, in healthy subjects
CN120837484A (zh) 柳穿鱼黄素在制备预防和/或治疗肺纤维化的药物中的应用
CN121796422A (zh) miR-3691抑制剂在制备治疗视网膜母细胞瘤的药物中的应用
WO2026081738A1 (zh) PI3Kα突变选择性抑制剂的用途
CN119868383A (zh) 桑皮苷a在制备预防和治疗肺纤维化疾病的药物中的应用
CN119770493A (zh) 一种改善或治疗急性髓系白血病的联合用药物组合物及其应用
JPH0262891A (ja) タンパク尿症改善剤
CN118593509A (zh) 非戈替尼作为抗三阴性乳腺癌药物bbdi的增敏剂的用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130710

Termination date: 20220109

CF01 Termination of patent right due to non-payment of annual fee